ClinicalTrials.gg
CompletedNCT06468956Updated Sep 3, 2026

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

A Phase 3 interventional study of SHR-1819 and Placebo in Moderate to Severe Atopic Dermatitis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
652
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 2 of them phase 3. Dermatitis, Atopic · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
Largest of 14
652 · median 159
Started
2024
with 1 other
Phase 3
3 of 14
1 open now
Registered
7th of 14
by date

Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., this one has the largest enrollment, is one of 2 that started in 2024, is one of 3 in phase 3, and was the 7th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.

03

Conditions studied

  • Moderate to Severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily sign forms prior to the commencement of any proceedings related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical research protocol;
  2. The age was ≥18 at the time of signing the informed consent and gender is unlimited;
  3. Atopic dermatitis at screening (according to the 2014 American Society of Dermatology guideline criteria, see Annex 1) and disease duration for at least 1 year before screening as judged by the investigator;
  4. EASI ≥ 16, IGA ≥ 3, BSA ≥ 10% during the screening and baseline periods;
  5. TCS was not optimal or not tolerated by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. Major surgeries are planned for the duration of the study;
  3. History of previous atopic corneal conjunctivitis involving the cornea;
  4. History of diseases (e.g., circulatory system abnormalities, endocrine system abnormalities, neurological disorders, hematologic disorders, immune system disorders, psychiatric disorders, and metabolic instability) that the researcher believes that participation in the study poses a risk to the safety of the subject or that the disease/illness worsens during the study period will affect the effectiveness or safety analysis;
  5. Subjects have had or are currently clinically significant diseases or abnormalities;
  6. Screening for people with a history of heavy alcohol consumption or substance abuse in the 3 months prior to screening;
  7. The drug has been used in the previous 6 months;
  8. Screening of subjects with within the first 5 years (except completely cured cervical cancer in situ and non- cutaneous squamous cell carcinoma or basal cell carcinoma);
  9. Other comorbid (or co-occurring) skin disorders may be affected in the study evaluation;
  10. Any cause that the researchers believe would prevent the participants from participating in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
652 participants (actual)

Study arms

  • Experimental
    SHR-1819 injection dose 1

    Drug: SHR-1819

  • Experimental
    SHR-1819 injection dose 2

    Drug: SHR-1819

  • Placebo comparator
    placebo

    Drug: Placebo

Interventions

  • SHR-1819 injection

  • DrugPlacebo

    placebo

06

What researchers measure

Primary outcomes

  1. At 16 weeks, the proportion of subjects who achieved eczema area and severity index (EASI) -75 (EASI score decreased ≥75% from baseline)

    The extent of area is assessed using the EASI scale

    Time frame: up to 16 weeks

  2. At week 16, the proportion of participants with an overall investigator assessment (IGA) score of 0 or 1 and a decrease of ≥2 points from baseline

    The overall degree of improvement was assessed using the IGA scale

    Time frame: up to 16 week

Secondary outcomes

  1. The proportion of subjects whose weekly mean of the daily (PP-NRS) score decreased by 4 points from baseline at Week 16

    Prtch improvement was assessed using the pruritus scale

    Time frame: up to 16 weeks

  2. At week 16, the proportion of subjects who achieved EASI-90 (EASI score ≥90% lower than baseline)

    The extent of area is assessed using the EASI scale

    Time frame: up to 16 weeks

  3. Proportion of subjects reaching EASI-75 at other visit viewpoints

    The extent of area is assessed using the EASI scale

    Time frame: up to 52 weeks

  4. The proportion of subjects with IGA score of 0 or 1 and 2 points from baseline

    The overall degree of improvement was assessed using the IGA scale

    Time frame: up to 52 weeks

  5. Proproportion of subjects with a 2 points from baseline at each iGA

    The overall degree of improvement was assessed using the IGA scale

    Time frame: up to 52 weeks

  6. Percentage of change and change from baseline in EASI per visit viewpoint

    The extent of area is assessed using the EASI scale

    Time frame: up to 52 weeks

  7. Percentage of subjects with weekly mean PP-NRS scores of 3 points from baseline

    Prtch improvement was assessed using the pruritus scale

    Time frame: up to 52 weeks

  8. Percentage of change and change from baseline in the Skin Quality of Life Index Questionnaire (DLQI) score at each visit viewpoint

    Subject quality of life was assessed using the DLQI scale

    Time frame: From the beginning of administration to the 52 week

  9. Percentage of change from baseline in eczema self-assessment (POEM) scores at each viewpoint

    Subject quality of life was assessed using the POEM scale

    Time frame: From the beginning of administration to the 52 week

  10. The time of SHR-1819 in the serum

    The concentration of SHR-1819 in plasma will be determined

    Time frame: From the beginning of administration to the 52th week

  11. The concentration of SHR-1819 in serum: AUC

    The concentration of SHR-1819 in plasma will be determined

    Time frame: From the beginning of administration to the 52th week

  12. Changes in the level of IgE in the serum

    Changes in the level of biomarkers in serum

    Time frame: From the beginning of administration to the 52th week

07

Study locations

1 site
  • Shanghai Fudan University HuaShan Hospital
    Shanghai, Shanghai Municipality 200040, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Aug 2026, 26 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 26 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
Jun 21, 2024
StartActual
Jun 14, 2024
Primary completionActual
Aug 26, 2026
CompletionActual
Aug 26, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06468956
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Jun 14, 2024
Primary completion
Aug 26, 2026
Completion
Aug 26, 2026
Last update
Sep 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1819

Start the discussion